1,959.70
+0.92%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IPCA Laboratories
Its shares trade on NSE under the ticker IPCALAB.NS. It has been listed since 23 February 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹95.63bn and net income of ₹11.41bn. At that date it held total assets of ₹123.70bn and shareholders' equity of ₹80.64bn.
Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Feb 1994
- Employees
- 16,167
- Website
- ipca.com ↗
Leadership
Pay as last reported
- Shri. Premchand GodhaExecutive Chairman of the Board, since 1975₹123.0m
- Mr. Pranay GodhaChief Executive Officer, Managing Director, Executive Director, since 2006₹65.2m
- Mr. Ajit JainChief Financial Officer, Managing Director, Executive Director, since 1994₹84.4m
- Mr. Pabitra BhattacharyaPresident - Operations (API)
- Mr. Sunil GhaiPresident - Marketing
- Dr. Sanjay KapadiaPresident - Corporate Quality Assurance
- Dr. Ashok KumarPresident - Research and Development (Chemicals)
- Mr. Shailesh LaulPresident - Operations (Formulations)
- Mr. Hitesh MaheshwariPresident - Research and Development (Formulations)
- Mr. Shashil MendonsaPresident - International Marketing
- Mr. Saidutta NandaPresident Human Resources
- Dr. Anil PareekPresident - Medical Affairs and Clinical Research
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 84
- Social
- 99
- Governance
- 45
- Direct emissions (scope 1)
- 169,992 t
- Energy emissions (scope 2)
- 124,512 t
- Value chain emissions (scope 3)
- 287,887 t
- Women in the workforce
- 5.66218%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ipca Laboratories manufactures 350 formulations and 80 APIs across multiple therapeutic segments.
- The company operates 18 manufacturing units in India for API and formulation production.
- Ipca Laboratories sells products in over 100 countries globally with diverse brand portfolios.
Weaknesses
- The company's API portfolio includes Atenolol and Metoprolol, which face market saturation.
- Ipca's brand portfolio features Zerodol and Lariago, which have limited international recognition.
- The firm's manufacturing units are concentrated in India, increasing supply chain vulnerability.
Opportunities
- Expanding API offerings to include Hydroxychloroquine sulfate and Losartan for global demand.
- Increasing market share in the Indian pharmaceutical sector with 16,167 employees.
- Growing presence in the European market through subsidiaries like Ipca Laboratories (U.K.) Ltd.
Threats
- Competition from global pharmaceutical firms in the Indian market with similar APIs.
- Regulatory changes affecting API manufacturing in India could disrupt production.
- Overreliance on the Indian manufacturing base may lead to geopolitical risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.